Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PHGEBearishCorporate Developmentsnews

High materiality8/10

BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review

Nov 26, 2025, 1:46 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The shares are retreating and nearing a 52-week low, reflecting investor concern over the FDA hold. Historical price drops often follow clinical holds, leading to decreased market confidence.

AI summary

What happened, with direct paths to the underlying reporting

FDA continues evaluation of nebulizer for BX004 injections in cystic fibrosis. Clinical hold on Phase 2b trial due to device data requests. DMC recommends continuation of study with adjusted dosing after safety review. Cash is sufficient to fund operations into early 2026; topline results expected then. PHGE shares down 7.18%, nearing 52-week low of $4.65.

FDA continues evaluation of nebulizer for BX004 injections in cystic fibrosis.
Clinical hold on Phase 2b trial due to device data requests.
DMC recommends continuation of study with adjusted dosing after safety review.
Cash is sufficient to fund operations into early 2026; topline results expected then.
PHGE shares down 7.18%, nearing 52-week low of $4.65.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.